Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,416.00
Bid: 12,408.00
Ask: 12,410.00
Change: -12.00 (-0.10%)
Spread: 2.00 (0.016%)
Open: 12,474.00
High: 12,480.00
Low: 12,350.00
Prev. Close: 12,428.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-AstraZeneca further cuts EU vaccine supply target to 30 mln -document

Fri, 12th Mar 2021 08:08

* Cut to about 30 mln doses, a third of contract's goal

* CEO in Feb pledged to try to deliver 40 mln

* To deliver 20 mln to EU in April -document
(Adds delivery data for EU countries)

By Francesco Guarascio

BRUSSELS, March 12 (Reuters) - AstraZeneca cut its
supply forecast of COVID-19 vaccine to the European Union in the
first quarter to about 30 million doses, a third of its
contractual obligations and a 25% drop from pledges made last
month, a document seen by Reuters shows.

The shortfall is a further blow to EU's vaccination plans
already being hampered by repeated delays in supply and a slow
rollout in some nations.

The AstraZeneca document, shared with EU officials and dated
March 10, shows that the company now expects to deliver 30.1
million doses by the end of March, and another 20 million in
April.

On Feb. 25, AstraZeneca boss Pascal Soriot told the European
Parliament that the company would try to deliver 40 million
doses by the end of March.

The document shows that on Feb. 24, the Anglo-Swedish
company had estimated a supply of only 34 million doses to the
EU for the January to March period, well below its contracted
target of 90 million doses.

The new cut follows a decision last week by Italy and the
European Commission to block a shipment of AstraZeneca vaccines
from Italy to Australia, in the first application of an EU
mechanism that allows the bloc to refuse export requests from
vaccine makers that do not comply with EU supply contracts.

A spokesman for AstraZeneca declined to comment on Friday.

A person familiar with the situation said that the increased
deliveries the company had expected for the first quarter did
not materialise because of difficulties in moving vaccines
through global supply chains.

The United States, from where AstraZeneca expected to partly
supply the EU market, told the EU that it would not export
AstraZeneca shots in the near future, Reuters reported on
Thursday, citing EU officials.

The company had said its initial supply cuts were caused by
production problems in the EU.

'NOT BEST EFFORTS'

"I see efforts, but not "best efforts". That's not good
enough yet for AstraZeneca to meet its Q1 obligations," EU
industry commissioner Thierry Breton said on Twitter late on
Thursday.
"It's time for AstraZeneca's Board to exercise its fiduciary
responsibility and now do what it takes to fulfil AZ's
commitments," Breton added.

AstraZeneca has committed to making its "best reasonable
efforts" to meet the targets set in its contract with the EU,
which foresees delivery of 300 million doses from December to
the end of June. The vaccine was approved for use in the EU in
late January.

The AstraZeneca document also shows that the company expects
to deliver about 20 million doses to the EU in April, more than
half of that in the last week. It includes no forecasts for May
or June.

AstraZeneca has committed to supplying the 27-nation bloc
with 180 million doses between April and June.

But EU countries since February have updated their
vaccination plans to include only half of the contracted doses
after AstraZeneca told them it was facing difficulties.

Germany, the largest country in the bloc, is expected to
receive 19% of the AstraZeneca supplies to the EU between next
week and the end of April, or a total of about 6 million doses,
including over 2 million in the last week of the month, the
document shows.

France should receive nearly 15% of the total, or about 4.7
million shots. Italy, with almost 14% of the overall expected
supplies, is to get 4.4 million by the end of April, the
document shows.
(Reporting by Francesco Guarascio @fraguarascio; editing by
Rosalba O'Brien and Jason Neely)

More News
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.